|
1C5W
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
Deposited 1999-12-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Not recorded
|
FLC CITRATE ANION × 3
ESI 4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；LMW human uPA/A145 was concentrated to 10 mg/ml and
incubated in 50 mM HEPES, 5.0 mM NaCl. pH 7.0, 1.4 mM
4-iodobenzo[b]thiophene-2-carboxamidine for 15 min on ice.
The complex was crystallized by vapor diffusion in hanging drops containing
equal volumes of protein-inhibitor solution (0.28 mM uPA/A145, 1.4 mM
inhibitor) and well solution (20 % 2-propanol, 20 % PEG 4K,
100 mM sodium citrate, pH 6.5) sealed over the well.
|
Resolution 1.94 Å
R-free 0.211
|
|
1C5X
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
Deposited 1999-12-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Not recorded
|
FLC CITRATE ANION × 3
ESI 4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；LMW human uPA/A145 was concentrated to 10 mg/ml and
incubated in 50 mM HEPES, 5.0 mM NaCl. pH 7.4, 1.4 mM
4-iodobenzo[b]thiophene-2-carboxamidine for 15 min on ice.
The complex was crystallized by vapor diffusion in hanging drops
containing equal volumes of protein-inhibitor solution (0.28 mM uPA/A145,
1.4 mM inhibitor) and well solution (20 % 2-propanol, 20 % PEG 4K,
100 mM sodium citrate, pH 6.5) sealed over the well.
|
Resolution 1.75 Å
R-free 0.244
|
|
1C5Y
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
Deposited 1999-12-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Not recorded
|
FLC CITRATE ANION × 3
ESP THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；LMW human uPA/A145 was concentrated to 10 mg/ml
and incubated in 50 mM HEPES, 5.0 mM NaCl. pH 7.0,
5.0 mM thieno[2,3-b]pyridine-2-carboxamidine for 15 min on ice.
The complex was crystallized by vapor diffusion in hanging
drops containing equal volumes of protein-inhibitor solution
(0.28 mM uPA/A145, 1.4 mM inhibitor and well solution
(20 % 2-propanol, 20 % PEG 4K, 100 mM sodium citrate,
pH 6.5) sealed over the well.
|
Resolution 1.65 Å
R-free 0.246
|
|
1C5Z
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
Deposited 1999-12-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Not recorded
|
FLC CITRATE ANION × 3
BEN BENZAMIDINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；LMW human uPA/A145 was concentrated to 10 mg/ml
and incubated in 50 mM HEPES, 5.0 mM NaCl. pH 7.0,
5.0 mM benzamidne for 15 min on ice. The complex was
crystallized by vapor diffusion in hanging drops containing
equal volumes of protein-inhibitor solution (0.28 mM uPA/A145,
1.4 mM inhibitor) and well solution (20 % 2-propanol,
20 % PEG 4K, 100 mM sodium citrate, pH 6.5) sealed over the well.
|
Resolution 1.85 Å
R-free 0.237
|
|
1EJN
UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN INHIBITOR COMPLEX
Deposited 2000-04-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
159–411（253 aa）
Fragment：B CHAIN
|
Mutation：C279S
|
SO4 SULFATE ION × 1
AGB N-(1-ADAMANTYL)-N'-(4-GUANIDINOBENZYL)UREA × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.2；298 K；pH 5.2, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.80 Å
R-free 0.240
|
|
1F5L
UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-AMILORIDE COMPLEX
Deposited 2000-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
159–411（253 aa）
Fragment：B CHAIN
|
Mutation：C279S
|
SO4 SULFATE ION × 2
AMR 3,5-DIAMINO-N-(AMINOIMINOMETHYL)-6-CHLOROPYRAZINECARBOXAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.2；298 K；pH 5.2, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.10 Å
R-free 0.250
|
|
1F92
UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI-1D COMPLEX
Deposited 2000-07-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
159–411（253 aa）
Fragment：B CHAIN
|
Mutation：C279S
|
SO4 SULFATE ION × 2
UKP [2,4,6-TRIISOPROPYL-PHENYLSULFONYL-L-[3-AMIDINO-PHENYLALANINYL]]-N'-BETA-ALANINYL-PIPERAZINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.2；298 K；pH 5.2, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.60 Å
R-free 0.248
|
|
1FV9
Crystal structure of human microurokinase in complex with 2-amino-5-hydroxy-benzimidazole
Deposited 2000-09-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–423（245 aa）
Fragment：B CHAIN (16-243)
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 1
172 2-AMINO-5-HYDROXY-BENZIMIDAZOLE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.15M LiSo4, 20% PEG 4000, succinate buffer, VAPOR DIFFUSION, HANGING DROP, temperature 18K
|
Resolution 3.00 Å
|
|
1GI7
A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
Deposited 2001-01-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–423（245 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A
|
120 2-(2-OXO-1,2-DIHYDRO-PYRIDIN-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE × 1
CIT CITRIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.79 Å
R-free 0.220
|
|
1GI8
A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
Deposited 2001-01-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–423（245 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A
|
CIT CITRIC ACID × 2
BMZ 2-(2-HYDROXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.75 Å
R-free 0.254
|
|
1GI9
A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
Deposited 2001-01-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–423（245 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A
|
123 2-(2-HYDROXY-5-METHOXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE × 1
CIT CITRIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.80 Å
R-free 0.238
|
|
1GJ7
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
Deposited 2001-04-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A
|
CIT CITRIC ACID × 2
132 6-CHLORO-2-(2-HYDROXY-BIPHENYL-3-YL)-1H-INDOLE-5-CARBOXAMIDINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.50 Å
R-free 0.230
|
|
1GJ8
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
Deposited 2001-04-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A
|
CIT CITRIC ACID × 2
133 6-FLUORO-2-(2-HYDROXY-3-ISOBUTOXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.64 Å
R-free 0.221
|
|
1GJ9
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
Deposited 2001-04-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A
|
CIT CITRIC ACID × 2
134 6-FLUORO-2-[2-HYDROXY-3-(2-METHYL-CYCLOHEXYLOXY)-PHENYL]-1H-INDOLE-5-CARBOXAMIDINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.80 Å
R-free 0.222
|
|
1GJA
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
Deposited 2001-04-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A
|
CIT CITRIC ACID × 2
135 N-(4-CARBAMIMIDOYL-PHENYL)-2-HYDROXY-BENZAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.56 Å
R-free 0.209
|
|
1GJB
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
Deposited 2001-04-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A
|
CIT CITRIC ACID × 2
130 2-(2-HYDROXY-BIPHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.90 Å
R-free 0.259
|
|
1GJC
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
Deposited 2001-04-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A
|
CIT CITRIC ACID × 2
130 2-(2-HYDROXY-BIPHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.73 Å
R-free 0.242
|
|
1GJD
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
Deposited 2001-05-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A
|
CIT CITRIC ACID × 2
136 N-(4-CARBAMIMIDOYL-3-CHORO-PHENYL)-2-HYDROXY-3-IODO-5-METHYL-BENZAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.75 Å
R-free 0.189
|
|
1KDU
SEQUENTIAL 1H NMR ASSIGNMENTS AND SECONDARY STRUCTURE OF THE KRINGLE DOMAIN FROM UROKINASE
Deposited 1993-07-15
|
Different construct
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
69–153（85 aa）
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
mmCIF provides none of the parsed conditions
|
Resolution not provided
|
|
1LMW
LMW U-PA Structure complexed with EGRCMK (GLU-GLY-ARG Chloromethyl Ketone)
Deposited 1995-07-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Chain B
179–431（253 aa）
|
Not recorded
|
0GJ L-alpha-glutamyl-N-{(1S)-4-{[amino(iminio)methyl]amino}-1-[(1S)-2-chloro-1-hydroxyethyl]butyl}glycinamide × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.50 Å
|
|
1LMW
LMW U-PA Structure complexed with EGRCMK (GLU-GLY-ARG Chloromethyl Ketone)
Deposited 1995-07-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain C
156–178（23 aa）
Chain D
179–431（253 aa）
|
Not recorded
|
0GJ L-alpha-glutamyl-N-{(1S)-4-{[amino(iminio)methyl]amino}-1-[(1S)-2-chloro-1-hydroxyethyl]butyl}glycinamide × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.50 Å
|
|
1O3P
Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors
Deposited 2003-03-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A
|
CIT CITRIC ACID × 2
655 2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-6-(CYCLOPENTYLOXY)BENZENOLATE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.81 Å
R-free 0.249
|
|
1O5A
Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)
Deposited 2003-09-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A/S190A
|
696 3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-1,1'-BIPHENYL-2-OLATE × 1
CIT CITRIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.5, pH 6.50
|
Resolution 1.68 Å
R-free 0.245
|
|
1O5B
Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)
Deposited 2003-09-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A/S190A
|
ESI 4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE × 1
CIT CITRIC ACID × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.5, pH 6.50
|
Resolution 1.85 Å
R-free 0.240
|
|
1O5C
Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)
Deposited 2003-09-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A/S190A
|
CR9 2-{5-[AMINO(IMINIO)METHYL]-6-FLUORO-1H-BENZIMIDAZOL-2-YL}-6-[(2-METHYLCYCLOHEXYL)OXY]BENZENOLATE × 1
CIT CITRIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.5, pH 6.50
|
Resolution 1.63 Å
R-free 0.219
|
|
1OWD
Substituted 2-Naphthamidine inhibitors of urokinase
Deposited 2003-03-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–423（245 aa）
Fragment：residues 179-423
|
Not recorded
|
497 6-[AMINO(IMINO)METHYL]-N-[(4R)-4-ETHYL-1,2,3,4-TETRAHYDROISOQUINOLIN-6-YL]-2-NAPHTHAMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.32 Å
R-free 0.313
|
|
1OWE
Substituted 2-Naphthamidine inhibitors of urokinase
Deposited 2003-03-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–423（245 aa）
Fragment：residues 179-423
|
Not recorded
|
SO4 SULFATE ION × 3
675 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.60 Å
R-free 0.236
|
|
1OWH
Substituted 2-Naphthamidine Inhibitors of Urokinase
Deposited 2003-03-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–423（245 aa）
Fragment：residues 179-423
|
Not recorded
|
SO4 SULFATE ION × 3
239 6-[(Z)-AMINO(IMINO)METHYL]-N-[4-(AMINOMETHYL)PHENYL]-2-NAPHTHAMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.61 Å
R-free 0.265
|
|
1OWI
Substituted 2-Naphthamidine Inhibitors of Urokinase
Deposited 2003-03-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–423（245 aa）
Fragment：residues 179-423
|
Not recorded
|
426 6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.93 Å
R-free 0.349
|
|
1OWJ
Substituted 2-Naphthamidine Inhibitors of Urokinase
Deposited 2003-03-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–423（245 aa）
Fragment：residues 179-423
|
Not recorded
|
155 6-[(Z)-AMINO(IMINO)METHYL]-N-(1-ISOPROPYL-3,4-DIHYDROISOQUINOLIN-7-YL)-2-NAPHTHAMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 3.10 Å
R-free 0.344
|
|
1OWK
Substituted 2-Naphthamidine Inhibitors of Urokinase
Deposited 2003-03-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–423（245 aa）
Fragment：residues 179-423
|
Not recorded
|
303 6-[(Z)-AMINO(IMINO)METHYL]-N-(1-ISOPROPYL-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL)-2-NAPHTHAMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.80 Å
R-free 0.236
|
|
1SC8
Urokinase Plasminogen Activator B-Chain-J435 Complex
Deposited 2004-02-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
164–425（262 aa）
Fragment：B Chain
|
Mutation：C122S
|
SO4 SULFATE ION × 2
2IN N-(BENZYLSULFONYL)SERYL-N~1~-{4-[AMINO(IMINO)METHYL]BENZYL}GLYCINAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.2；277 K；sodium citrate, ammonium sulfate, litium sulfate, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.40 Å
R-free 0.240
|
|
1SQA
Substituted 2-Naphthamidine Inhibitors of Urokinase
Deposited 2004-03-18
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–423（245 aa）
|
Not recorded
|
SO4 SULFATE ION × 3
UI1 6-[(Z)-AMINO(IMINO)METHYL]-N-[4-(AMINOMETHYL)PHENYL]-4-(PYRIMIDIN-2-YLAMINO)-2-NAPHTHAMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
R-free 0.266
|
|
1SQO
Substituted 2-Naphthamidine Inhibitors of Urokinase
Deposited 2004-03-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–423（245 aa）
|
Not recorded
|
SO4 SULFATE ION × 3
UI2 8-(PYRIMIDIN-2-YLAMINO)NAPHTHALENE-2-CARBOXIMIDAMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.84 Å
R-free 0.284
|
|
1SQT
Substituted 2-Naphthamidine Inhibitors of Urokinase
Deposited 2004-03-19
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–423（245 aa）
|
Not recorded
|
UI3 7-METHOXY-8-[1-(METHYLSULFONYL)-1H-PYRAZOL-4-YL]NAPHTHALENE-2-CARBOXIMIDAMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.90 Å
R-free 0.236
|
|
1U6Q
Substituted 2-Naphthamadine inhibitors of Urokinase
Deposited 2004-07-30
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–423（245 aa）
Fragment：Residues 179-423
|
Not recorded
|
745 TRANS-6-(2-PHENYLCYCLOPROPYL)-NAPHTHALENE-2-CARBOXAMIDINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.02 Å
R-free 0.290
|
|
1URK
SOLUTION STRUCTURE OF THE AMINO TERMINAL FRAGMENT OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
Deposited 1994-01-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
26–155（130 aa）
|
Not recorded
|
FUC alpha-L-fucopyranose × 1
|
SOLUTION NMR
mmCIF provides none of the parsed conditions
|
Resolution not provided
|
|
1VJ9
Urokinase Plasminogen Activator B-Chain-JT464 Complex
Deposited 2004-02-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
164–425（262 aa）
Fragment：B Chain
|
Mutation：C122S
|
SO4 SULFATE ION × 2
5IN N-(BENZYLSULFONYL)-L-SERYL-N~1~-{4-[AMINO(IMINO)METHYL]BENZYL}-O-BENZYL-L-SERINAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.2；277 K；sodium citrate, ammonium sulfate, lithium sulfate, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.40 Å
R-free 0.247
|
|
1VJA
Urokinase Plasminogen Activator B-Chain-JT463 Complex
Deposited 2004-02-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
164–425（262 aa）
Fragment：B Chain
|
Mutation：C122S
|
SO4 SULFATE ION × 2
7IN N-(BENZYLSULFONYL)SERYL-N~1~-{4-[(Z)-AMINO(IMINO)METHYL]BENZYL}SERINAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.2；277 K；sodium citrate, ammonium sulfate, lithium sulfate, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.00 Å
R-free 0.232
|
|
1W0Z
Urokinase type plasminogen activator
Deposited 2004-06-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–425（247 aa）
Fragment：RESIDUES 179-425
|
Not recorded
|
SI1 N-(BUTYLSULFONYL)-D-SERYL-N-{4-[AMINO(IMINO)METHYL]BENZYL}-L-ALANINAMIDE × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K
|
Resolution 1.90 Å
R-free 0.221
|
|
1W10
Urokinase type plasminogen activator
Deposited 2004-06-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–425（247 aa）
Fragment：RESIDUES 179-425
|
Not recorded
|
SJ1 N-(ISOBUTOXYCARBONYL)-D-SERYL-N-((1S)-4-{[AMINO(IMINO)METHYL]AMINO}-1-FORMYLBUTYL)-L-ALANINAMIDE × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K
|
Resolution 2.00 Å
|
|
1W11
UROKINASE TYPE PLASMINOGEN ACTIVATOR
Deposited 2004-06-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–425（247 aa）
Fragment：RESIDUES 179-425
|
Not recorded
|
SO4 SULFATE ION × 2
SK1 N-(BENZYLSULFONYL)-D-SERYL-N-{4-[AMINO(IMINO)METHYL]BENZYL}-L-ALANINAMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
R-free 0.249
|
|
1W12
UROKINASE TYPE PLASMINOGEN ACTIVATOR
Deposited 2004-06-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–425（247 aa）
Fragment：RESIDUES 179-425
|
Not recorded
|
SL1 N-((1S)-4-{[AMINO(IMINO)METHYL]AMINO}-1-FORMYLBUTYL)-2-{(3R)-3-[(BENZYLSULFONYL)AMINO]-2-OXO-5-PHENYL-2,3-DIHYDRO-1H-1,4-BENZODIAZEPIN-1-YL}ACETAMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.40 Å
R-free 0.261
|
|
1W13
UROKINASE TYPE PLASMINOGEN ACTIVATOR
Deposited 2004-06-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–425（247 aa）
Fragment：RESIDUES 179-425
|
Not recorded
|
SM1 N-(BENZYLSULFONYL)-D-SERYL-N-(4-{[AMINO(IMINO)METHYL]AMINO}BENZYL)-L-ALANINAMIDE × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
R-free 0.230
|
|
1W14
UROKINASE TYPE PLASMINOGEN ACTIVATOR
Deposited 2004-06-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–425（247 aa）
Fragment：RESIDUES 179-425
|
Not recorded
|
SO4 SULFATE ION × 2
SH1 N-[(2-PHENYLETHYL)SULFONYL]-D-SERYL-N-[(1S)-4-[(DIAMINOMETHYLENE)AMINO]-1-(HYDROXYMETHYL)BUTYL]-L-ALANINAMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.20 Å
R-free 0.253
|
|
2FD6
Structure of Human Urokinase Plasminogen Activator in Complex with Urokinase Receptor and an anti-upar antibody at 1.9 A
Deposited 2005-12-13
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
31–152（122 aa）
Fragment：Amino terminal residues 31-152
|
Not recorded
|
SO4 SULFATE ION × 1
ETX 2-ETHOXYETHANOL × 3
EDO 1,2-ETHANEDIOL × 2
PGE TRIETHYLENE GLYCOL × 1
NDG 2-acetamido-2-deoxy-alpha-D-glucopyranose × 1
PG4 TETRAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
MICRODIALYSIS；pH 6.5；298 K；4% PEG4000, 5% ethylene glycol, 5% methanol, 0.05% sodium azide, 50 mM cacodylate, pH 6.5, MICRODIALYSIS, temperature 298K
|
Resolution 1.90 Å
R-free 0.276
|
|
2FD6
Structure of Human Urokinase Plasminogen Activator in Complex with Urokinase Receptor and an anti-upar antibody at 1.9 A
Deposited 2005-12-13
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
31–152（122 aa）
Fragment：Amino terminal residues 31-152
|
Not recorded
|
SO4 SULFATE ION × 1
ETX 2-ETHOXYETHANOL × 3
EDO 1,2-ETHANEDIOL × 2
PGE TRIETHYLENE GLYCOL × 1
NDG 2-acetamido-2-deoxy-alpha-D-glucopyranose × 1
PG4 TETRAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
MICRODIALYSIS；pH 6.5；298 K；4% PEG4000, 5% ethylene glycol, 5% methanol, 0.05% sodium azide, 50 mM cacodylate, pH 6.5, MICRODIALYSIS, temperature 298K
|
Resolution 1.90 Å
R-free 0.276
|
|
2I9A
Crystal structure of the free aminoterminal fragment of urokinase type plasminogen activator (ATF)
Deposited 2006-09-05
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
21–163（143 aa）
Fragment：N-terminal fragment of urokinase, residues 21-163
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 10.5；293 K；1.2 M sodium dihydrogen phosphate, 0.8 M potassium hydrogen phosphate, 200 mM lithium sulfate, 100 mM CHES, pH 10.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.208
|
|
2I9A
Crystal structure of the free aminoterminal fragment of urokinase type plasminogen activator (ATF)
Deposited 2006-09-05
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
21–163（143 aa）
Fragment：N-terminal fragment of urokinase, residues 21-163
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 10.5；293 K；1.2 M sodium dihydrogen phosphate, 0.8 M potassium hydrogen phosphate, 200 mM lithium sulfate, 100 mM CHES, pH 10.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.208
|
|
2I9A
Crystal structure of the free aminoterminal fragment of urokinase type plasminogen activator (ATF)
Deposited 2006-09-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
21–163（143 aa）
Fragment：N-terminal fragment of urokinase, residues 21-163
|
Not recorded
|
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 10.5；293 K；1.2 M sodium dihydrogen phosphate, 0.8 M potassium hydrogen phosphate, 200 mM lithium sulfate, 100 mM CHES, pH 10.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.208
|
|
2I9A
Crystal structure of the free aminoterminal fragment of urokinase type plasminogen activator (ATF)
Deposited 2006-09-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
21–163（143 aa）
Fragment：N-terminal fragment of urokinase, residues 21-163
|
Not recorded
|
PO4 PHOSPHATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 10.5；293 K；1.2 M sodium dihydrogen phosphate, 0.8 M potassium hydrogen phosphate, 200 mM lithium sulfate, 100 mM CHES, pH 10.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.208
|
|
2I9B
Crystal structure of ATF-urokinase receptor complex
Deposited 2006-09-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
21–163（143 aa）
Fragment：ATF, residues 21-163
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；22.5% w/v PEG3350, 200 mM ammonium sulfate, 100 mM Bis-Tris, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.80 Å
R-free 0.265
|
|
2I9B
Crystal structure of ATF-urokinase receptor complex
Deposited 2006-09-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
21–163（143 aa）
Fragment：ATF, residues 21-163
|
Not recorded
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；22.5% w/v PEG3350, 200 mM ammonium sulfate, 100 mM Bis-Tris, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.80 Å
R-free 0.265
|
|
2I9B
Crystal structure of ATF-urokinase receptor complex
Deposited 2006-09-05
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain C
21–163（143 aa）
Fragment：ATF, residues 21-163
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；22.5% w/v PEG3350, 200 mM ammonium sulfate, 100 mM Bis-Tris, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.80 Å
R-free 0.265
|
|
2I9B
Crystal structure of ATF-urokinase receptor complex
Deposited 2006-09-05
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Other combination
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain D
21–163（143 aa）
Fragment：ATF, residues 21-163
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；22.5% w/v PEG3350, 200 mM ammonium sulfate, 100 mM Bis-Tris, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.80 Å
R-free 0.265
|
|
2VIN
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
Deposited 2007-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–431（253 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 179-431
|
Mutation：YES
|
ACT ACETATE ION × 1
SO4 SULFATE ION × 1
505 (2R)-1-(2,6-dimethylphenoxy)propan-2-amine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.6；PROTEIN WAS CRYSTALLIZED FROM 22-24% PEG4000, 0.17M (NH4)2SO4, 15% GLYCEROL, 0.1M NA(CH3COO) PH=4.0; THEN SOAKED IN 0.05M COMPOUND, 27.5% PEG4000, 0.2M HEPES PH=6.6, 0.1M (NH4)(CH3COO)
|
Resolution 1.90 Å
R-free 0.235
|
|
2VIO
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
Deposited 2007-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–431（253 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 179-431
|
Mutation：YES
|
ACT ACETATE ION × 1
L1O 4-(2-aminoethoxy)-3,5-dichlorobenzoic acid × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.6；PROTEIN WAS CRYSTALLIZED FROM 22-24% PEG4000, 0.17M (NH4)2SO4, 15% GLYCEROL, 0.1M NA(CH3COO) PH=4.0; THEN SOAKED IN 0.05M COMPOUND, 28% PEG4000, 0.29M HEPES PH=6.6, 5% GLYCEROL
|
Resolution 1.80 Å
R-free 0.250
|
|
2VIP
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
Deposited 2007-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–431（253 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 179-431
|
Mutation：YES
|
ACT ACETATE ION × 1
SO4 SULFATE ION × 1
L1R 4-(2-AMINOETHOXY)-3,5-DICHLORO-N-[3-(1-METHYLETHOXY)PHENYL]BENZAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.6；PROTEIN WAS CRYSTALLIZED FROM 22-24% PEG4000, 0.17M (NH4)2SO4, 15% GLYCEROL, 0.1M NA(CH3COO) PH=4.0; THEN SOAKED IN 0.01M COMPOUND, 28% PEG4000, 0.29M HEPES PH=6.6, 5% GLYCEROL, 0.001M NA(CH3COO), 0.001M (NH4)2SO4, 10% DMSO
|
Resolution 1.72 Å
R-free 0.237
|
|
2VIQ
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
Deposited 2007-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–431（253 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 179-431
|
Mutation：YES
|
ACT ACETATE ION × 1
D55 4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.6；PROTEIN WAS CRYSTALLIZED FROM 22-24% PEG4000, 0.17M (NH4)2SO4, 15% GLYCEROL, 0.1M NA(CH3COO) PH=4.0; THEN SOAKED IN 0.04M COMPOUND, 28% PEG4000, 5% GLYCEROL, 0.29M BISTRIS PH=6.6, 0.001M NA(CH3COO), 0.001M (NH4)2SO4
|
Resolution 2.00 Å
R-free 0.264
|
|
2VIV
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
Deposited 2007-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–431（253 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 179-431
|
Mutation：YES
|
ACT ACETATE ION × 1
VG2 4-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.6；PROTEIN WAS CRYSTALLIZED FROM 22-24% PEG4000, 0.17M (NH4)2SO4, 15% GLYCEROL, 0.1M NA(CH3COO) PH=4.0; THEN SOAKED IN 0.04M COMPOUND, 28% PEG4000, 5% GLYCEROL, 0.29M BISTRIS PH=6.6, 0.001M NA(CH3COO), 0.001M (NH4)2SO4
|
Resolution 1.72 Å
R-free 0.238
|
|
2VIW
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
Deposited 2007-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–431（253 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 179-431
|
Mutation：YES
|
ACT ACETATE ION × 1
D56 4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.6；PROTEIN WAS CRYSTALLIZED FROM 22-24% PEG4000, 0.17M (NH4)2SO4, 15% GLYCEROL, 0.1M NA(CH3COO) PH=4.0; THEN SOAKED IN 0.001M COMPOUND, 28% PEG4000, 5% GLYCEROL, 0.29M BISTRIS PH=6.6, 0.001M NA(CH3COO), 0.001M (NH4)2SO4
|
Resolution 2.05 Å
R-free 0.260
|
|
2VNT
Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE
Deposited 2008-02-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
156–431（276 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 156-431
|
Not recorded
|
QGG 1-({4-CHLORO-1-[(DIAMINOMETHYLIDENE)AMINO]ISOQUINOLIN-7-YL}SULFONYL)-D-PROLINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.20 Å
R-free 0.295
|
|
2VNT
Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE
Deposited 2008-02-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
156–431（276 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 156-431
|
Not recorded
|
QGG 1-({4-CHLORO-1-[(DIAMINOMETHYLIDENE)AMINO]ISOQUINOLIN-7-YL}SULFONYL)-D-PROLINE × 1
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.20 Å
R-free 0.295
|
|
2VNT
Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE
Deposited 2008-02-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
156–431（276 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 156-431
|
Not recorded
|
QGG 1-({4-CHLORO-1-[(DIAMINOMETHYLIDENE)AMINO]ISOQUINOLIN-7-YL}SULFONYL)-D-PROLINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.20 Å
R-free 0.295
|
|
2VNT
Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE
Deposited 2008-02-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
156–431（276 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 156-431
|
Not recorded
|
QGG 1-({4-CHLORO-1-[(DIAMINOMETHYLIDENE)AMINO]ISOQUINOLIN-7-YL}SULFONYL)-D-PROLINE × 1
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.20 Å
R-free 0.295
|
|
2VNT
Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE
Deposited 2008-02-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain E
156–431（276 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 156-431
|
Not recorded
|
QGG 1-({4-CHLORO-1-[(DIAMINOMETHYLIDENE)AMINO]ISOQUINOLIN-7-YL}SULFONYL)-D-PROLINE × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.20 Å
R-free 0.295
|
|
2VNT
Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE
Deposited 2008-02-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain F
156–431（276 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 156-431
|
Not recorded
|
QGG 1-({4-CHLORO-1-[(DIAMINOMETHYLIDENE)AMINO]ISOQUINOLIN-7-YL}SULFONYL)-D-PROLINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.20 Å
R-free 0.295
|
|
3BT1
Structure of urokinase receptor, urokinase and vitronectin complex
Deposited 2007-12-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
21–153（133 aa）
Fragment：urokinase amino terminal fragment, Urokinase-type plasminogen activator long chain A, UNP residues 21-153
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
MICRODIALYSIS；pH 7.5；295 K；12% PEG 3350, 50mM HEPES pH 7.5, MICRODIALYSIS, temperature 295K
|
Resolution 2.80 Å
R-free 0.308
|
|
3BT2
Structure of urokinase receptor, urokinase and vitronectin complex
Deposited 2007-12-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain A
21–153（133 aa）
Fragment：urokinase amino terminal fragment, Urokinase-type plasminogen activator long chain A, UNP residues 21-153
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
MICRODIALYSIS；pH 7.5；295 K；8% PEG 4000, 2.5% ethanol, 0.05% sodium azide, 50mM cacodylate pH 6.5, pH 7.5, MICRODIALYSIS, temperature 295K
|
Resolution 2.50 Å
R-free 0.272
|
|
3BT2
Structure of urokinase receptor, urokinase and vitronectin complex
Deposited 2007-12-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
21–153（133 aa）
Fragment：urokinase amino terminal fragment, Urokinase-type plasminogen activator long chain A, UNP residues 21-153
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
MICRODIALYSIS；pH 7.5；295 K；8% PEG 4000, 2.5% ethanol, 0.05% sodium azide, 50mM cacodylate pH 6.5, pH 7.5, MICRODIALYSIS, temperature 295K
|
Resolution 2.50 Å
R-free 0.272
|
|
3KGP
Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol
Deposited 2009-10-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–431（253 aa）
Fragment：C-terminal domain, UNP residues 179-431
|
Mutation：C122A, N145Q
|
4AZ 4-(aminomethyl)benzoic acid × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；0.05M sodium citrate, 1.95M (NH4)2SO4, 0.05% NaN3, 5% PEG 400, pH 4.60, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.35 Å
R-free 0.274
|
|
3KHV
Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol
Deposited 2009-10-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–431（253 aa）
Fragment：C-terminal domain, UNP residues 179-431
|
Mutation：C122A, N145Q
|
4AL [4-(aminomethyl)phenyl]methanol × 1
SO4 SULFATE ION × 1
PGE TRIETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；0.05M sodium citrate, 1.95M (NH4)2SO4, 0.05% NaN3, 5% PEG 400, pH 4.60, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.35 Å
R-free 0.293
|
|
3KID
The Crystal Structures of 2-Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Plasminogen Activator
Deposited 2009-11-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
Fragment：C-terminal domain, UNP residues 179-431
|
Mutation：C122A, N145Q
|
2BS ethyl 2-amino-1,3-benzothiazole-6-carboxylate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；0.05M sodium citrate, 1.95M (NH4)2SO4, 0.05% NaN3, 5% PEG 400, pH 4.60, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.71 Å
R-free 0.275
|
|
3M61
Crystal structure of complex of urokinase and a upain-1 variant(W3A) in pH4.6 condition
Deposited 2010-03-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–431（253 aa）
Fragment：C-terminal domain, UNP residues 179-431
|
Mutation：C122A, N145Q
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.60, 5% PEG 400, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.68 Å
R-free 0.243
|
|
3MHW
The complex crystal Structure of Urokianse and 2-Aminobenzothiazole
Deposited 2010-04-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–425（247 aa）
Fragment：C-terminal domain, UNP residues 179-425
|
Mutation：C122S
|
SO4 SULFATE ION × 1
ABV 1,3-benzothiazol-2-amine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；0.05M sodium citrate, 1.95M (NH4)2SO4, 0.05% NaN3, 5% PEG 400, pH 4.6, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.45 Å
R-free 0.234
|
|
3MWI
The complex crystal Structure of Urokianse and 5-nitro-1H-indole-2-amidine
Deposited 2010-05-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–424（246 aa）
Fragment：C-terminal domain, UNP residues 179-424
|
Mutation：C122A
|
B25 5-nitro-1H-indole-2-carboximidamide × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；0.05M sodium citrate, 1.95M (NH4)2SO4, 0.05% NaN3, 5% PEG 400, pH 4.6, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.03 Å
R-free 0.297
|
|
3OX7
The crystal structure of uPA complex with peptide inhibitor MH027 at pH4.6
Deposited 2010-09-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–431（253 aa）
Fragment：C-TERMINAL DOMAIN, RESIDUES 179-431
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 1
PG4 TETRAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；0.05M SODIUM CITRATE, 1.95M (NH4)2SO4, 0.05% NAN3, 5% PEG 400, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.58 Å
R-free 0.230
|
|
3OY5
The crystal structure of uPA complex with peptide inhibitor MH027 at pH7.4
Deposited 2010-09-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–431（253 aa）
Fragment：C-TERMINAL DOMAIN, UNP residues 179-431
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；298 K；100mM Tris-Hcl, 2.0M (NH4)2SO4, 0.05% NAN3, 5% PEG 400, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.31 Å
R-free 0.231
|
|
3OY6
The crystal structure of uPA complex with peptide inhibitor MH036 at pH4.6
Deposited 2010-09-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–431（253 aa）
Fragment：C-TERMINAL DOMAIN, UNP residues 179-431
|
Mutation：C122A, N145Q
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；298 K；0.05M SODIUM CITRATE, 1.95M (NH4)2SO4, 0.05% NAN3, 5% PEG 400, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.31 Å
R-free 0.263
|
|
3QN7
Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)
Deposited 2011-02-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
179–431（253 aa）
Fragment：Catalytic domain, Urokinase-type plasminogen activator chain B
|
Mutation：C122A, N145Q
|
ZBR 1,3,5-tris(bromomethyl)benzene × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.3；293 K；2M ammonium sulfate, 0.05M sodium citrate, 5%(v/v) PEG 400, pH 4.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.252
|
|
4DVA
The crystal structure of human urokinase-type plasminogen activator catalytic domain
Deposited 2012-02-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–424（246 aa）
Fragment：catalytic domain
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 2
P6G HEXAETHYLENE GLYCOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate, 5% PEG400, pH 4.6, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.94 Å
R-free 0.244
|
|
4DW2
The crystal structure of uPA in complex with the Fab fragment of mAb-112
Deposited 2012-02-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain U
179–424（246 aa）
Fragment：catalytic domain, UNP RESIDUES 179-424
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；298 K；25% (w/v) PEG 2000 MME, 100mM Tris-HCl (pH 8.0), 0.21M ammonium sulfate, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.97 Å
R-free 0.300
|
|
4FU7
Crystal Structure of the Urokinase
Deposited 2012-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–424（246 aa）
|
Not recorded
|
SO4 SULFATE ION × 3
ACT ACETATE ION × 1
1UP 2-[(7-carbamimidoyl-2-methoxynaphthalen-1-yl)oxy]acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å
R-free 0.223
|
|
4FU8
Crystal Structure of the Urokinase
Deposited 2012-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–424（246 aa）
|
Not recorded
|
2UP naphthalene-2-carboximidamide × 1
ACT ACETATE ION × 2
SIN SUCCINIC ACID × 1
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.20 Å
R-free 0.239
|
|
4FU9
Crystal Structure of the Urokinase
Deposited 2012-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–424（246 aa）
|
Not recorded
|
SO4 SULFATE ION × 3
SIN SUCCINIC ACID × 1
GOL GLYCEROL × 6
ACT ACETATE ION × 2
675 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291 - 298.0K
|
Resolution 1.60 Å
R-free 0.182
|
|
4FUB
Crystal Structure of the Urokinase
Deposited 2012-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–424（246 aa）
|
Not recorded
|
4UP 6-[(2S,3S)-3-phenyloxiran-2-yl]naphthalene-2-carboximidamide × 1
SO4 SULFATE ION × 1
SIN SUCCINIC ACID × 1
GOL GLYCEROL × 6
15P POLYETHYLENE GLYCOL (N=34) × 1
ACT ACETATE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 1.90 Å
R-free 0.187
|
|
4FUC
Crystal Structure of the Urokinase
Deposited 2012-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–424（246 aa）
|
Not recorded
|
239 6-[(Z)-AMINO(IMINO)METHYL]-N-[4-(AMINOMETHYL)PHENYL]-2-NAPHTHAMIDE × 1
SIN SUCCINIC ACID × 1
SO4 SULFATE ION × 4
ACT ACETATE ION × 1
GOL GLYCEROL × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 1.72 Å
R-free 0.187
|
|
4FUD
Crystal Structure of the Urokinase
Deposited 2012-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–424（246 aa）
|
Not recorded
|
6UP 8-aminonaphthalene-2-carboximidamide × 1
SIN SUCCINIC ACID × 3
SO4 SULFATE ION × 4
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.00 Å
R-free 0.220
|
|
4FUE
Crystal Structure of the Urokinase
Deposited 2012-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–424（246 aa）
|
Not recorded
|
7UP 6-(1,2,3,4-tetrahydroisoquinolin-6-ylethynyl)naphthalene-2-carboximidamide × 1
SIN SUCCINIC ACID × 1
SO4 SULFATE ION × 2
GOL GLYCEROL × 3
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.00 Å
R-free 0.190
|
|
4FUF
Crystal Structure of the Urokinase
Deposited 2012-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–424（246 aa）
|
Not recorded
|
8UP 8-(3-bromopropoxy)-7-methoxynaphthalene-2-carboximidamide × 1
SIN SUCCINIC ACID × 1
SO4 SULFATE ION × 3
GOL GLYCEROL × 4
ACT ACETATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.00 Å
R-free 0.202
|
|
4FUG
Crystal Structure of the Urokinase
Deposited 2012-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–424（246 aa）
|
Not recorded
|
9UP methyl (7-carbamimidoylnaphthalen-1-yl)carbamate × 1
SO4 SULFATE ION × 4
GOL GLYCEROL × 2
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 1.80 Å
R-free 0.203
|
|
4FUH
Crystal Structure of the Urokinase
Deposited 2012-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–424（246 aa）
|
Not recorded
|
1U2 6-[(phenylcarbamoyl)amino]naphthalene-2-carboximidamide × 1
SO4 SULFATE ION × 4
ACT ACETATE ION × 1
GOL GLYCEROL × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 1.60 Å
R-free 0.183
|
|
4FUI
Crystal Structure of the Urokinase
Deposited 2012-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–424（246 aa）
|
Not recorded
|
UI3 7-METHOXY-8-[1-(METHYLSULFONYL)-1H-PYRAZOL-4-YL]NAPHTHALENE-2-CARBOXIMIDAMIDE × 1
SO4 SULFATE ION × 3
GOL GLYCEROL × 4
NA SODIUM ION × 1
SIN SUCCINIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.00 Å
R-free 0.209
|
|
4FUJ
Crystal Structure of the Urokinase
Deposited 2012-06-28
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
179–424（246 aa）
|
Not recorded
|
1U9 6-{(E)-2-[3-(2-hydroxyethyl)phenyl]ethenyl}naphthalene-2-carboximidamide × 1
SIN SUCCINIC ACID × 1
SO4 SULFATE ION × 2
ACT ACETATE ION × 2
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291 - 298.0K
|
Resolution 2.05 Å
R-free 0.205
|
|
4GLY
Human urokinase-type plasminogen activator uPA in complex with the two-disulfide bridge peptide UK504
Deposited 2012-08-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
179–423（245 aa）
Fragment：CATALYTIC DOMAIN, UROKINASE-TYPE PLASMINOGEN ACTIVATOR
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 4
NA SODIUM ION × 2
CL CHLORIDE ION × 3
P6G HEXAETHYLENE GLYCOL × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；293 K；1.8M Ammonium sulfate, 5% PEG400, 0.05% Sodium azide, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.52 Å
R-free 0.204
|
|
4H42
Synthesis of a Weak Basic uPA Inhibitor and Crystal Structure of Complex with uPA
Deposited 2012-09-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–426（248 aa）
Fragment：human urokinase-type plasminogen activator catalytic domain
|
Mutation：C122A, N145Q
|
11E N-[(2-amino-1,3-benzothiazol-6-yl)carbonyl]glycine × 1
PG6 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0 M ammonium sulfate, 50 mM sodium citrate pH 4.6 and 5% PEG400, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.01 Å
R-free 0.285
|
|
4JK5
Human urokinase-type Plasminogen Activator (uPA) in complex with a bicyclic peptide inhibitor (UK18-D-Ser)
Deposited 2013-03-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
179–423（245 aa）
Fragment：Catalytic domain
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 4
CL CHLORIDE ION × 2
P6G HEXAETHYLENE GLYCOL × 1
ZBR 1,3,5-tris(bromomethyl)benzene × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.9；293 K；50mM Na3(cit) pH 4.9, 5% v/v PEG400, 1.8M (NH4)2SO4, 0.05% NaN3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.55 Å
R-free 0.213
|
|
4JK6
Human urokinase-type Plasminogen Activator (uPA) in complex with a bicyclic peptide inhibitor (UK18-D-Aba)
Deposited 2013-03-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
179–423（245 aa）
Fragment：Catalytic domain
|
Mutation：C299A, N322Q
|
SO4 SULFATE ION × 4
CL CHLORIDE ION × 1
P6G HEXAETHYLENE GLYCOL × 1
ZBR 1,3,5-tris(bromomethyl)benzene × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.9；293 K；50mM Na3(cit) pH 4.9, 5% v/v PEG400, 1.8M (NH4)2SO4, 0.05% NaN3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å
R-free 0.205
|
|
4K24
Structure of anti-uPAR Fab ATN-658 in complex with uPAR
Deposited 2013-04-08
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain A
21–153（133 aa）
Fragment：UNP residues 21-153
|
Not recorded
|
MAN alpha-D-mannopyranose × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；0.1M HEPES pH 7.5, 55%(v/v) Tacsimate, 2%(v/v) 2-methyl-1,3-propanediol, vapor diffusion, sitting drop, temperature 295K
|
Resolution 4.50 Å
R-free 0.275
|
|
4MNV
Crystal structure of bicyclic peptide UK729 bound as an acyl-enzyme intermediate to urokinase-type plasminogen activator (uPA)
Deposited 2013-09-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 1
ACT ACETATE ION × 2
ZBR 1,3,5-tris(bromomethyl)benzene × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.25；291 K；21% PEG4000, 16% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.25, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.80 Å
R-free 0.216
|
|
4MNW
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK749
Deposited 2013-09-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 2
GOL GLYCEROL × 5
ACT ACETATE ION × 1
ZBR 1,3,5-tris(bromomethyl)benzene × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；22% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.49 Å
R-free 0.171
|
|
4MNX
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK811
Deposited 2013-09-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 2
GOL GLYCEROL × 1
29N 1,1',1''-(1,3,5-triazinane-1,3,5-triyl)tripropan-1-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；22% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.85 Å
R-free 0.227
|
|
4MNY
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK903
Deposited 2013-09-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 2
ACT ACETATE ION × 2
GOL GLYCEROL × 2
29O N,N',N''-benzene-1,3,5-triyltris(2-bromoacetamide) × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.25；291 K；20% PEG4000, 16% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.25, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.70 Å
R-free 0.215
|
|
4MNY
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK903
Deposited 2013-09-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 2
ACT ACETATE ION × 3
GOL GLYCEROL × 1
29O N,N',N''-benzene-1,3,5-triyltris(2-bromoacetamide) × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.25；291 K；20% PEG4000, 16% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.25, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.70 Å
R-free 0.215
|
|
4OS1
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK601 (bicyclic 1)
Deposited 2014-02-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 2
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；21% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.20 Å
R-free 0.227
|
|
4OS2
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK602 (bicyclic 1)
Deposited 2014-02-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 2
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；21% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.79 Å
R-free 0.207
|
|
4OS4
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK603 (bicyclic 1)
Deposited 2014-02-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 2
GOL GLYCEROL × 1
ACT ACETATE ION × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；21% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.00 Å
R-free 0.214
|
|
4OS5
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK603 (bicyclic 2)
Deposited 2014-02-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；21% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.26 Å
R-free 0.200
|
|
4OS6
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK604 (bicyclic 2)
Deposited 2014-02-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 2
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；21% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.75 Å
R-free 0.186
|
|
4OS7
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK607 (bicyclic)
Deposited 2014-02-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 3
ACT ACETATE ION × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；21% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.00 Å
R-free 0.198
|
|
4X0W
The crystal structure of mupain-1-17 in complex with murinised human uPA
Deposited 2014-11-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–425（247 aa）
Fragment：UNP RESIDUES 179-425
|
Mutation：H99Y, C122A, N145Q
|
MRZ piperidine-1-carboximidamide × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0 M ammonium sulfate, 50 mM sodium citrate pH 4.6, 5% PEG 400
|
Resolution 2.10 Å
R-free 0.272
|
|
4X1N
The crystal structure of mupain-1-16 in complex with murinised human uPA at pH7.4
Deposited 2014-11-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–425（247 aa）
Fragment：UNP RESIDUES 179-425
|
Mutation：C299A, H272Y, N322Q
|
MRZ piperidine-1-carboximidamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400
|
Resolution 1.80 Å
R-free 0.276
|
|
4X1P
The crystal structure of mupain-1-17 in complex with murinised human uPA at pH4.6
Deposited 2014-11-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–425（247 aa）
Fragment：catalytic domain (UNP RESIDUES 179-425)
|
Mutation：H99Y, C122A, N145Q
|
SO4 SULFATE ION × 2
PGE TRIETHYLENE GLYCOL × 2
MRZ piperidine-1-carboximidamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG400
|
Resolution 1.60 Å
R-free 0.211
|
|
4X1Q
The crystal structure of mupain-1 in complex with murinised human uPA at pH7.4
Deposited 2014-11-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–425（247 aa）
Fragment：catalytic domain (UNP RESIDUES 179-425)
|
Mutation：H99Y, C122A, N145Q
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400
|
Resolution 2.28 Å
R-free 0.287
|
|
4X1R
The crystal structure of mupain-1-12 in complex with murinised human uPA at pH7.4
Deposited 2014-11-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–425（247 aa）
Fragment：catalytic domain (UNP RESIDUES 179-425)
|
Mutation：H99Y, C122A, N145Q
|
PL0 1-phenylguanidine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400
|
Resolution 2.10 Å
R-free 0.273
|
|
4X1S
The crystal structure of mupain-1-16-D9A in complex with murinised human uPA at pH7.4
Deposited 2014-11-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–425（247 aa）
Fragment：catalytic domain (UNP RESIDUES 179-425)
|
Mutation：H99Y, C122A, N145Q
|
MRZ piperidine-1-carboximidamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400
|
Resolution 1.90 Å
R-free 0.249
|
|
4XSK
Structure of PAItrap, an uPA mutant
Deposited 2015-01-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–424（246 aa）
Fragment：UNP RESIDUES 162-407
|
Mutation：G37R, C122A, N145Q, S195A, R217L
|
SO4 SULFATE ION × 2
PGE TRIETHYLENE GLYCOL × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.2 M ammonium sulfate, 5% PEG 400, 50 mM sodium citrate (pH 4.6)
|
Resolution 1.50 Å
R-free 0.209
|
|
4ZHL
The crystal structure of mupain-1-IG in complex with murinised human uPA at pH7.4
Deposited 2015-04-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–425（247 aa）
Fragment：UNP RESIDUES 179-425
|
Mutation：H99Y, C122A, N145Q
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate, pH 4.6, 5% polyethylene glycol (PEG) 400
|
Resolution 2.06 Å
R-free 0.262
|
|
4ZHM
The crystal structure of mupain-1--16-IG in complex with murinised human uPA at pH7.4
Deposited 2015-04-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–425（247 aa）
Fragment：UNP RESIDUES 179-425
|
Mutation：H99Y, C122A, N145Q
|
MRZ piperidine-1-carboximidamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate, pH 4.6, 5% polyethylene glycol (PEG) 400
|
Resolution 1.90 Å
R-free 0.264
|
|
4ZKN
The crystal structure of upain-1-W3A in complex with uPA at pH5.5
Deposited 2015-04-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–425（247 aa）
Fragment：UNP residues 179-425
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 1
PG4 TETRAETHYLENE GLYCOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；50 mM sodium citrate pH 4.6, 2.0 M ammonium sulfate supplemented with 5% PEG 400
|
Resolution 1.36 Å
R-free 0.265
|
|
4ZKO
The crystal structure of upain-1-W3A in complex with uPA at pH7.4
Deposited 2015-04-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain U
179–425（247 aa）
Fragment：UNP residues 179-425
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 1
P6G HEXAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；50 mM sodium citrate pH 4.6, 2.0 M ammonium sulfate supplemented with 5% PEG 400
|
Resolution 1.29 Å
R-free 0.225
|
|
4ZKR
The crystal structure of upain-1-W3A in complex with uPA at pH9.0
Deposited 2015-04-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–425（247 aa）
Fragment：UNP residues 179-425
|
Mutation：C122A, N145Q
|
SO4 SULFATE ION × 1
P6G HEXAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50 mM sodium citrate pH 4.6, 2.0 M ammonium sulfate supplemented with 5% PEG400
|
Resolution 1.36 Å
R-free 0.234
|
|
4ZKS
The crystal structure of upain-1-W3A in complex with inactive uPA (uPA-S195A) at pH7.4
Deposited 2015-04-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–425（247 aa）
Fragment：UNP residues 179-425
|
Mutation：C122A, N145Q, S195A
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；50 mM sodium citrate pH 4.6, 2.0 M ammonium sulfate supplemented with 5% PEG400
|
Resolution 1.85 Å
R-free 0.245
|
|
5HGG
Crystal structure of uPA in complex with a camelid-derived antibody fragment
Deposited 2016-01-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
179–424（246 aa）
Fragment：UNP residues 179-424
Chain B
179–424（246 aa）
Fragment：UNP residues 179-424
|
Mutation：C122A, N145Q
Mutation：C122A, N145Q
|
GOL GLYCEROL × 5
SO4 SULFATE ION × 2
TWN (3S)-3-[(2S,3S,4R)-3,4-DIMETHYLTETRAHYDROFURAN-2-YL]BUTYL LAURATE × 3
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.25；289 K；Sodium Phosphate dibasic, Ammonium Sulfate, MES, Tween 20
|
Resolution 1.97 Å
R-free 0.196
|
|
5WXF
Crystal structure of uPA in complex with upain-2-2
Deposited 2017-01-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50 mM sodium citrate, pH 4.6, and 2.0 M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.46 Å
R-free 0.245
|
|
5WXO
Crystal structure of uPA in complex with upain-2-2-W3A
Deposited 2017-01-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.64 Å
R-free 0.221
|
|
5WXP
Crystal structure of uPA in complex with upain-2-3-W3A
Deposited 2017-01-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q
|
ALA ALANINE × 1
CYS CYSTEINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.75 Å
R-free 0.249
|
|
5WXQ
Crystal structure of uPA in complex with upain-2-4
Deposited 2017-01-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.79 Å
R-free 0.212
|
|
5WXR
Crystal structure of uPA in complex with upain-2-4-W3A
Deposited 2017-01-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.75 Å
R-free 0.234
|
|
5WXS
Crystal structure of uPA in complex with S2444
Deposited 2017-01-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q
|
7YF (2R)-N-[2-[[(2S)-5-carbamimidamido-1-oxidanylidene-pentan-2-yl]amino]-2-oxidanylidene-ethyl]-5-oxidanylidene-1,2-dihydropyrrole-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 2.30 Å
R-free 0.266
|
|
5WXT
Crystal structure of uPA-S195A in complex with S2444
Deposited 2017-01-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q/S376A
|
7YR 5-oxo-D-prolylglycyl-N-(4-nitrophenyl)-L-argininamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50 mM sodium citrate, pH 4.6, and 2.0 M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 2.10 Å
R-free 0.266
|
|
5XG4
Crystal structure of uPA in complex with quercetin
Deposited 2017-04-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–424（246 aa）
Fragment：UNP residues 179-424
|
Not recorded
|
QUE 3,5,7,3',4'-PENTAHYDROXYFLAVONE × 1
PG6 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 3.00 Å
R-free 0.258
|
|
5YC6
The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH4.6
Deposited 2017-09-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–424（246 aa）
Fragment：Urokinase-type plasminogen activator chain B, UNP residues 179-324
|
Not recorded
|
PZH 1-(4-BROMOPHENYL)METHANAMINE × 1
SO4 SULFATE ION × 1
PGE TRIETHYLENE GLYCOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate (pH 4.6), 2.0M ammonium sulfate supplemented with 5% PEG 400
|
Resolution 1.18 Å
R-free 0.228
|
|
5YC7
The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH7.4
Deposited 2017-09-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–424（246 aa）
Fragment：Urokinase-type plasminogen activator chain B, UNP residues 179-324
|
Not recorded
|
PZH 1-(4-BROMOPHENYL)METHANAMINE × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate (pH 4.6), 2.0M ammonium sulfate supplemented with 5% PEG 400
|
Resolution 2.00 Å
R-free 0.262
|
|
5Z1C
The crystal structure of uPA in complex with 4-Iodobenzylamine at pH7.4
Deposited 2017-12-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–423（245 aa）
|
Mutation：C299U,N322U
|
ZXI 1-(4-iodophenyl)methanamine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate (pH 4.6), 2.0M ammonium sulfate supplemented with 5% PEG 400
|
Resolution 1.45 Å
R-free 0.143
|
|
5ZA7
uPA-HMA
Deposited 2018-02-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q
|
HMX 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.70 Å
R-free 0.227
|
|
5ZA8
uPA-BB2-27F
Deposited 2018-02-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q
|
27I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(1-methylpyrazol-4-yl)pyrazine-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.90 Å
R-free 0.233
|
|
5ZA9
uPA-BB2-50F
Deposited 2018-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q
|
50I 3-azanyl-5-(azepan-1-yl)-6-(1-benzofuran-2-yl)-Ncarbamimidoyl-pyrazine-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.62 Å
R-free 0.236
|
|
5ZAE
uPA-6F-HMA
Deposited 2018-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q
|
EAU 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.73 Å
R-free 0.276
|
|
5ZAF
uPA-BB2-28F
Deposited 2018-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
162–414（253 aa）
|
Mutation：C122A, N145Q
|
28I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-3-yl)pyrazine-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.65 Å
R-free 0.236
|
|
5ZAG
uPA-BB2-94F
Deposited 2018-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q
|
94I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-pyrimidin-5-yl-pyrazine-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.95 Å
R-free 0.225
|
|
5ZAH
uPA-BB2-30F
Deposited 2018-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q
|
30I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(2-methoxypyrimidin-5-yl)pyrazine-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 2.98 Å
R-free 0.268
|
|
5ZAJ
uPA-31F
Deposited 2018-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q
|
32I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.65 Å
R-free 0.239
|
|
5ZC5
uPA-NU-09F
Deposited 2018-02-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q
|
09I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(4-fluoranyl-1-benzofuran-2-yl)pyrazine-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.90 Å
R-free 0.235
|
|
6AG2
uPA-HMA
Deposited 2018-08-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q
|
9X9 3,5-bis(azanyl)-N-carbamimidoyl-6-(2-methoxypyrimidin-5-yl)pyrazine-2-carboxamide × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；2.0M ammonium sulfate, 50mM sodium citrate (pH 4.6), 5% PEG 400
|
Resolution 1.77 Å
R-free 0.252
|
|
6AG3
Crystal structure of uPA in complex with 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide
Deposited 2018-08-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q
|
9XC 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 2.48 Å
R-free 0.267
|
|
6AG7
The crystal structure of uPA in complex with HMA-55F
Deposited 2018-08-09
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–423（245 aa）
|
Not recorded
|
H55 3,5-diamino-N-carbamimidoyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50 mM sodium citrate, pH 4.6, and 2.0 M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.90 Å
R-free 0.228
|
|
6AG9
Crystal structure of uPA in complex with 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyrazine-2- carboxamide
Deposited 2018-08-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q
|
9XF 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyrazine-2-carboxamide × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.63 Å
R-free 0.206
|
|
6JYP
Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide
Deposited 2019-04-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–424（246 aa）
|
Mutation：H99Y,C122A,N145Q
|
HMX 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.05M sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 2.25 Å
R-free 0.254
|
|
6JYQ
Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide
Deposited 2019-04-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–424（246 aa）
|
Mutation：H99Y,C122A,N145Q
|
EAU 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.05M sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.75 Å
R-free 0.263
|
|
6L04
Crystal structure of uPA_H99Y in complex with 31F
Deposited 2019-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–423（245 aa）
|
Mutation：H99Y,C122A,N145Q
|
32I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5%
PEG 400
|
Resolution 2.21 Å
R-free 0.217
|
|
6L05
Crystal structure of uPA_H99Y in complex with 50F
Deposited 2019-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–423（245 aa）
|
Mutation：H99Y,C122A,N145Q
|
50I 3-azanyl-5-(azepan-1-yl)-6-(1-benzofuran-2-yl)-Ncarbamimidoyl-pyrazine-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5%
PEG 400
|
Resolution 2.49 Å
R-free 0.261
|
|
6NMB
Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator
Deposited 2019-01-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
164–431（268 aa）
Fragment：UNP residues 164-431
|
Not recorded
|
NO3 NITRATE ION × 1
AMH TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.03 M sodium nitrate, 0.03 M sodium phosphate, 0.03 M ammonium sulfate, 0.1 M Tris bicine, 25% v/v PEG500, 10% v/v PEG20000
|
Resolution 2.30 Å
R-free 0.271
|
|
6NMB
Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator
Deposited 2019-01-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
164–431（268 aa）
Fragment：UNP residues 164-431
|
Not recorded
|
NO3 NITRATE ION × 1
AMH TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.03 M sodium nitrate, 0.03 M sodium phosphate, 0.03 M ammonium sulfate, 0.1 M Tris bicine, 25% v/v PEG500, 10% v/v PEG20000
|
Resolution 2.30 Å
R-free 0.271
|
|
6NMB
Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator
Deposited 2019-01-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
164–431（268 aa）
Fragment：UNP residues 164-431
|
Not recorded
|
NO3 NITRATE ION × 1
AMH TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.03 M sodium nitrate, 0.03 M sodium phosphate, 0.03 M ammonium sulfate, 0.1 M Tris bicine, 25% v/v PEG500, 10% v/v PEG20000
|
Resolution 2.30 Å
R-free 0.271
|
|
6NMB
Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator
Deposited 2019-01-10
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
164–431（268 aa）
Fragment：UNP residues 164-431
|
Not recorded
|
NO3 NITRATE ION × 1
AMH TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.03 M sodium nitrate, 0.03 M sodium phosphate, 0.03 M ammonium sulfate, 0.1 M Tris bicine, 25% v/v PEG500, 10% v/v PEG20000
|
Resolution 2.30 Å
R-free 0.271
|
|
6XVD
Crystal structure of complex of urokinase and a upain-1 variant(W3F) in pH7.4 condition
Deposited 2020-01-21
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain U
162–414（253 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；0.05 M sodium citrate at pH 4.5, 1.95 M (NH4)2SO4, 0.05% NaN3, and 5% PEG400
|
Resolution 1.40 Å
R-free 0.203
|
|
7DZD
Crystal structure of uPA in complex with cleaved camostat
Deposited 2021-01-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–423（245 aa）
|
Mutation：C122A,N145Q
|
GBS 4-carbamimidamidobenzoic acid × 1
PGE TRIETHYLENE GLYCOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400
|
Resolution 2.00 Å
R-free 0.231
|
|
7VM4
Crystal structure of uPA in complex with nafamostat
Deposited 2021-10-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–423（245 aa）
|
Not recorded
|
GBS 4-carbamimidamidobenzoic acid × 1
PGE TRIETHYLENE GLYCOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；2.0 M ammonium sulfate, 5% PEG400, 20 mM sodium citrate, pH 4.6
|
Resolution 2.01 Å
R-free 0.224
|
|
7VM5
Crystal structure of uPA in complex with 4-guanidinobenzoic acid
Deposited 2021-10-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–424（246 aa）
|
Not recorded
|
PGE TRIETHYLENE GLYCOL × 1
GBS 4-carbamimidamidobenzoic acid × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0 M ammonium sulfate, 5% PEG 400, 20 mM sodium citrate, pH 4.6
|
Resolution 1.97 Å
R-free 0.247
|
|
7VM6
Crystal structure of uPA in complex with 6-amidino-2-naphthol
Deposited 2021-10-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–426（248 aa）
|
Not recorded
|
7R8 6-oxidanylnaphthalene-2-carboximidamide × 1
SO4 SULFATE ION × 1
PGE TRIETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0 M ammonium sulfate, 5% PEG 400, 20 mM sodium citrate, pH 4.6
|
Resolution 1.79 Å
R-free 0.243
|
|
7VM7
Crystal structure of inactive uPA in complex with nafamostat
Deposited 2021-10-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain U
179–423（245 aa）
|
Not recorded
|
7RF (6-carbamimidoylnaphthalen-2-yl) 4-carbamimidamidobenzoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0 M ammonium sulfate, 5% PEG 400, 20 mM sodium citrate, pH 4.6
|
Resolution 1.87 Å
R-free 0.242
|
|
7ZRR
Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inhibitor UK965
Deposited 2022-05-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
154–431（278 aa）
|
Not recorded
|
1PE PENTAETHYLENE GLYCOL × 1
EDO 1,2-ETHANEDIOL × 2
NH2 AMINO GROUP × 1
ZBR 1,3,5-tris(bromomethyl)benzene × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.3；293 K；5% PEG400, 50mM Citrato pH 4.3, 1.8 M (NH4)2SO4, 20% Ethylene glycol
|
Resolution 1.64 Å
R-free 0.239
|
|
7ZRT
Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inhibitor UK970
Deposited 2022-05-05
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
162–414（253 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
PEG DI(HYDROXYETHYL)ETHER × 2
EDO 1,2-ETHANEDIOL × 3
1PE PENTAETHYLENE GLYCOL × 1
ZBR 1,3,5-tris(bromomethyl)benzene × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.3；293 K；7% PEG400, 50mM Citrato, 1.8 M (NH4)2SO4; 20% Ethylene glycol
|
Resolution 1.80 Å
R-free 0.229
|
|
9PYF
uPA Inhibitory Fab AB2 Complex
Deposited 2025-08-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
156–425（270 aa）
|
Mutation：C122A
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298.15 K；For crystallization purposes, uPA was co-incubated with AB2 in a 1:1 stoichiometric ratio for 1h and co-purified using size-exclusion chromatography. The complex co-eluted was concentrated to 15 mg/mL.Crystallization drops were produced by mixing 0.1 uL of uPA-AB2 solution with 0.1 uL of the respective crystallization solution. A single crystal was produced using a solution containing 0.2 M diammonium hydrogen citrate (Salt) and 20 percent PEG 3350 and incubating the experiment for 14 days at room temperature.
|
Resolution 2.90 Å
R-free 0.300
|
